$TSHA News

Taysha Gene Therapies: Shortened Timeline Increases The Potential

Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026

Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights

Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility

Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary

Taysha Gene Therapies Q1 Earnings Call Highlights

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies To Reveal New Preclinical Data Supporting Construct Design Of TSHA-102 For Rett Syndrome At The ASGCT 2026 Annual Meeting

Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels

This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy

Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment

Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $17

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)